<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

AI update: medical software and pre-emption

In light of the rapidly expanding field of medical software technology, and...

Read More

Dyadic International: Working to change the game i...

Key learnings:

Read More

What life sciences companies need to know about pr...

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Exploring life sciences investment trends with Min...

Key learnings: Leading US life sciences law firm Mintz has been active in t...

Read More

Key challenges to scaling up early-stage investmen...

Access to venture capital and effective fundraising tactics are key to buil...

Read More

The value potential of blockchain in healthcare: Q...

More than nine in 10 (91%) health executive respondents believe blockchain ...

Read More

Growing opportunities in cannabinoid-based treatme...

In June 2018 it was announced that venture capital firm Casa Verde Capital,...

Read More

Realising the potential of cannabinoid-related the...

On 10-11 October 2018, investors, industry stakeholders, and senior executi...

Read More

Infographic: Spotlight on the US Life Sciences Sec...

Silicon Valley Bank’s mid-year report, Trends in Healthcare Investments and...

Read More

Accessing US Government Funds for Research and Dev...

The US Government has long been a significant source of funds for life scie...

Read More

Novoheart expands global presence to support comme...

Key learnings: Novoheart has developed human bioengineered heart constructs...

Read More

Carmell Therapeutics advances plasma-based product...

Key learnings: Carmell™ Therapeutics closed its Series B round in June 2017...

Read More

Add Your Response